Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial

医学 诱导化疗 吉西他滨 临床终点 内科学 肿瘤科 鼻咽癌 危险系数 顺铂 化疗 放化疗 多中心试验 脱氧胞苷 胃肠病学 临床试验 随机对照试验 放射治疗 多中心研究 置信区间
作者
Yuan Zhang,Lei Chen,Guoqing Hu,Ning Zhang,Xiao‐Dong Zhu,Kunyu Yang,Feng Jin,Mei Shi,Yu‐Pei Chen,Wei‐Han Hu,Zhibin Cheng,Siyang Wang,Ye Tian,Xicheng Wang,Yan Ping Sun,Jingao Li,Wen‐Fei Li,Yuhong Li,Yan‐Ping Mao,Guan‐Qun Zhou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (22): 2420-2425 被引量:175
标识
DOI:10.1200/jco.22.00327
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized trial, patients were assigned to be treated with concurrent chemoradiotherapy alone (standard therapy, n = 238) or gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy (n = 242). With a median follow-up of 69.8 months, the induction chemotherapy group had a significantly higher 5-year OS (87.9% v 78.8%, hazard ratio, 0.51 [95% CI 0.34 to 0.78]; P = .001) and a comparable risk of late toxicities (≥ grade 3, 11.3% v 11.4%). Notably, the depth of the tumor response to induction chemotherapy correlated significantly and positively with survival (complete response v partial response v stable/progressive disease, 5-year OS, 100% v 88.4% v 61.5%, P = .005). Besides, patients with a low pretreatment cell-free Epstein-Barr virus DNA load (< 4,000 copies/mL) might not benefit from induction chemotherapy (5-year OS, 90.6% v 91.4%, P = .77). In conclusion, induction chemotherapy before concurrent chemoradiotherapy improved OS significantly in patients with locally advanced nasopharyngeal carcinoma, without increasing the risk of late toxicities. Tumor response to induction chemotherapy and pretreatment cell-free Epstein-Barr virus DNA might be useful to guide individualized treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lll发布了新的文献求助20
1秒前
mjw完成签到,获得积分10
1秒前
搜集达人的应助被Aster采纳,获得30
2秒前
3秒前
左丘芷卉完成签到,获得积分10
4秒前
小玲发布了新的文献求助30
4秒前
5秒前
Akim的应助被阔达冷荷采纳,获得10
5秒前
NexusExplorer的应助被bushiCC采纳,获得10
7秒前
深情安青的应助被日桉采纳,获得10
7秒前
8秒前
10秒前
青雾雨发布了新的文献求助30
10秒前
唯钰完成签到,获得积分10
10秒前
12秒前
12秒前
李健的应助被北林采纳,获得200
13秒前
领导范儿的应助被gbh采纳,获得10
13秒前
renn发布了新的文献求助10
14秒前
晚风完成签到 ,获得积分10
14秒前
噜噜完成签到,获得积分10
14秒前
丘比特的应助被QQ采纳,获得10
14秒前
汉堡包的应助被123采纳,获得10
15秒前
15秒前
完美世界的应助被小艾采纳,获得10
16秒前
苏打水518完成签到,获得积分10
16秒前
16秒前
17秒前
17秒前
Hui发布了新的文献求助10
18秒前
18秒前
CodeCraft的应助被vickylow采纳,获得10
18秒前
科研陈完成签到,获得积分10
19秒前
水天需发布了新的文献求助10
19秒前
19秒前
汉堡包的应助被godsky采纳,获得10
20秒前
20秒前
冬眠完成签到,获得积分10
20秒前
20秒前
天天快乐的应助被ZZ采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648